Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Assets (2016 - 2025)

Fortress Biotech (FBIO) has 13 years of Assets data on record, last reported at $181.4 million in Q3 2025.

  • For Q3 2025, Assets rose 42.74% year-over-year to $181.4 million; the TTM value through Sep 2025 reached $181.4 million, up 42.74%, while the annual FY2024 figure was $144.2 million, 13.91% down from the prior year.
  • Assets reached $181.4 million in Q3 2025 per FBIO's latest filing, up from $159.9 million in the prior quarter.
  • Across five years, Assets topped out at $418.2 million in Q2 2021 and bottomed at $127.1 million in Q3 2024.
  • Average Assets over 5 years is $256.0 million, with a median of $181.4 million recorded in 2025.
  • Peak YoY movement for Assets: soared 70.94% in 2021, then tumbled 43.08% in 2023.
  • A 5-year view of Assets shows it stood at $396.5 million in 2021, then decreased by 25.78% to $294.3 million in 2022, then crashed by 43.08% to $167.5 million in 2023, then dropped by 13.91% to $144.2 million in 2024, then increased by 25.78% to $181.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $181.4 million in Q3 2025, $159.9 million in Q2 2025, and $178.1 million in Q1 2025.